Shots:
- Samsung Bioepis has launched Obodence (60mg PFS) & Xbryk (120mg vial), biosimilar versions of Prolia & Xgeva, for bone health treatments, with commercial availability expected by Dec 2025 & Jan 2026, respectively
- Obodence treats postmenopausal women & men with osteoporosis at high fracture risk, glucocorticoid-induced osteoporosis in both sexes, & bone loss in men on hormone ablation for prostate cancer
- Xbryk prevents SREs in adults with bone-involved malignancies, treats giant cell tumors of bone in adults & skeletally mature adolescents with unresectable or high-morbidity tumors
Ref: Businesswire| Image: Samsung Bioepis | Press Release
Related News:- Samsung Bioepis Reports the EC’s approval of Obodence & Xbryk (Biosimilar, Denosumab)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
